5-chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one | 683240-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 5-chloro-6-methyl-1,3-dihydrobenzimidazol-2-one
• CAS: 683240-81-5
• 化学式: C₈H₇ClN₂O
• mdl: MFCD15143569
• 分子量: 182.609
• InChiKey: ZURRVGUCXLHILL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 储存条件：
  存储条件：2-8°C，密封，干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Chloro-6-methylbenzoimidazol-2-one
Synonyms: 5-Chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Chloro-6-methylbenzoimidazol-2-one
CAS number: 683240-81-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7ClN2O
Molecular weight: 182.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 1-(6-chloro-5-methyl-1H-benzo[d]imidazol-2-yl)-N-cyclopentylpiperidine-4-carboxamide
  参考文献：
  名称：

  [EN] MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS
  [FR] INHIBITEURS DE PROSTAGLANDINE E SYNTHASE-1 (MPGES1) MICROSOMALE

  摘要：

  公式（I）的化合物，以及其药用盐，以及包括该化合物的药物组合物。该化合物用于治疗选择自炎性疾病、伤害性疼痛、自身免疫疾病、呼吸系统疾病、发热、癌症、与炎症相关的厌食症、阿尔茨海默病和心血管疾病的紊乱。

  公开号：

  WO2011023812A1
• 作为产物：
  描述：

  4-氯-5-甲基苯-1,2-二胺 、 N,N'-羰基二咪唑 以 四氢呋喃 为溶剂， 反应 3.0h， 以80%的产率得到5-chloro-6-methyl-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  [EN] PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGE-1 INHIBITORS
  [FR] DÉRIVÉS DE PIPÉRIDINYLBENZOIMIDAZOLE UTILISÉS COMME INHIBITEURS DE MPGE-1

  摘要：

  化合物(R)-1-(5-氯-6-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-(四氢呋喃-3-基)哌啶-4-羧酰胺和(R)-1-(6-氯-6-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-(四氢呋喃-3-基)哌啶-4-羧酰胺，以及其药学上可接受的盐，以及包含这些化合物中的任何一种的药物组合物。这些化合物可用于治疗和/或预防炎症性疾病；自身免疫疾病；疼痛；呼吸障碍；癌症；心血管疾病；神经退行性疾病；骨疾病；由家族性腺瘤性息肉症（FAP）引起的疾病；膀胱过度活跃；发热；以及与炎症相关的厌食症。

  公开号：

  WO2014204371A1

文献信息

• [EN] PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INIHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINYL BENZOIMIDAZOLE COMME INHIBITEURS DE MPGES-1
  申请人：NOVASAID AB

  公开号：WO2012117062A1

  公开（公告）日：2012-09-07

  A compound of formula (I) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, pain, auto-immune disease, breathing disorders, fever, cancer, inflammation related anorexia, overactive bladder, familial adenomatous polyposis (FAP) condition, neurodegenerative diseases, bone diseases and cardiovascular diseases.

  式（I）的化合物及其药用盐，以及包含该化合物的药物组合物。该化合物可用于治疗选择自炎症性疾病、疼痛、自身免疫疾病、呼吸系统疾病、发热、癌症、与炎症相关的厌食症、膀胱过度活跃、家族性腺瘤性息肉病（FAP）病情、神经退行性疾病、骨病和心血管疾病的混合物。
• [EN] NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS PIPÉRIDINYLE BENZOIMIDAZOLE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
  申请人：CADILA PHARMACEUTICALS LTD

  公开号：WO2014204370A1

  公开（公告）日：2014-12-24

  The compounds 1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol- 2-yl)-N-((3S,4R)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide and l-(6-chloro-5- methy1-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-N-((3S,4R)-4- hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compound are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (FAP) condition; overactive bladder; fever; and inflammation-related anorexia.

  化合物1-(5-氯-6-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-((3S,4R)-4-羟基四氢呋喃-3-基)哌啶-4-甲酰胺和1-(6-氯-5-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-((3S,4R)-4-羟基四氢呋喃-3-基)哌啶-4-甲酰胺，以及其药学上可接受的盐，以及包含这些化合物中任何一种的药物组合物。这些化合物可用于治疗和/或预防选择自炎症性疾病；自身免疫疾病；疼痛；呼吸障碍；癌症；心血管疾病；神经退行性疾病；骨疾病；由家族性腺瘤性息肉症（FAP）病情导致的障碍；膀胱过度活跃；发热；以及与炎症相关的厌食症的障碍。
• Vanilloid receptor ligands and their use in treatments
  申请人：Amgen Inc.

  公开号：US20040152690A1

  公开（公告）日：2004-08-05

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, bums, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗苯并咪唑和含有苯并咪唑的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症病状、炎症性疼痛及相关的高敏感性和痛觉过敏、神经痛及相关的高敏感性和痛觉过敏、糖尿病神经病疼痛、烧伤后疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、头发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
• NOVEL PIPERIDINYL BENZOIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS
  申请人：NovaSAID AB

  公开号：US20160194308A1

  公开（公告）日：2016-07-07

  The compounds 1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-N-((3S,4R)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide and 1-(6-chloro-5-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1H-benzo[d]imidazol-2-yl)-N-((3S,4R)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compound are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (FAP) condition; overactive bladder; fever; and inflammation-related anorexia.

  化合物1-(5-氯-6-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-((3S,4R)-4-羟基四氢呋喃-3-基)哌啶-4-羧酰胺和1-(6-氯-5-甲基-1-(6-(三氟甲基)吡啶-2-基)-1H-苯并[d]咪唑-2-基)-N-((3S,4R)-4-羟基四氢呋喃-3-基)哌啶-4-羧酰胺，以及其药学上可接受的盐，和包含这些化合物中的任何一种的药物组合物。这些化合物可用于治疗和/或预防炎症性疾病；自身免疫性疾病；疼痛；呼吸系统疾病；癌症；心血管疾病；神经退行性疾病；骨质疾病；由家族性腺瘤性息肉症（FAP）引起的疾病；过度活跃的膀胱；发热；和与炎症相关的厌食症。
• VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
  申请人：Balan Chenera

  公开号：US20090143575A1

  公开（公告）日：2009-06-04

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotizing agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗苯并咪唑及其含量物，用于急性、炎症性和神经痛、牙痛、一般头痛、偏头痛、集群性头痛、混合血管和非血管综合症、紧张型头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱疾病、牛皮癣、有炎症成分的皮肤病、慢性炎症状况、炎症性疼痛和相关的高敏感性和触痛、神经痛和相关的高敏感性和触痛、糖尿病神经病疼痛、烧伤后疼痛、交感神经维持的疼痛、去感觉综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠疾病、胃溃疡、十二指肠溃疡、腹泻、坏死性剂引起的胃损伤、头发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。